ALT	Alanine-aminotransferase
AUROC	Area under the receiver operating characteristics
BMI	Body mass index
cACLD	Compensated advanced chronic liver disease
CSPH	Clinically significant portal hypertension
DAA	Direct-acting antivirals
EOT	End of treatment
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
INR	International normalized ratio
IQR	Interquartile range
LB3	Liver biopsy 3 years after EOT
LB6	Liver biopsy 6 years after EOT
LREs	Liver-related events
NITs	Non-invasive tests
PLT	Platelet count
T2DM	Type 2 diabetes mellitus
SVR	Sustained virological response
VCTE-LSM	Liver stiffness measurement by vibration-controlled transient elastography